“When we block the D2 receptor in humans, it is expected they will develop glucose intolerance, obesity, and sedentary behavior.” -Jane Plain, in her series on The physiology of body fat regulation. It’s probably true.
Cabergoline is primarily used to treat prolinactinoma, or prolactin-secreting tumors. In women (& men apparently), prolactin stimulates milk production; in men, it is associated with the refractory period after orgasm. In both genders, dopamine inhibits prolactin secretion. Cabergoline targets the D2 receptor, but it’s a dirty drug. It’s used off-label for gyno and to improve sexy times (Kruger et al., 2003 <– yes, that was actually tested).